Analizan la evolución de la enfermedad neumocócica causada por el serotipo 3 en España en las últimas tres décadas. Entre sus principales conclusiones se destaca que “la vacunación infantil no...
Read moreUna nueva investigación logra estratificar a las personas con artritis reumatoide según el riesgo de padecer eventos cardiovasculares a partir del análisis computacional de más de 30 tipos de mol...
Read moreLos hallazgos se centran en un método alternativo para el diagnóstico de la retinopatía diabética: la autofluorescencia cutánea
Read moreUn nuevo estudio dirigido por Nicolás Bologna, un investigador del CSIC en el CRAG, arroja luz sobre el papel crucial de la extensión N-terminal (NTE) de las proteínas AGO, ofreciendo así nuevas p...
Read moreInitial data from the IGNYTE clinical trial demonstrate that the combination of the oncolytic virus RP1 and nivolumab (PD-1 immune checkpoint inhibitor) provides durable and clinically significant ant...
Read moreAmong the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene editing using CRISPR-Cas9, techniques that are positioning Spain as a benchmark in...
Read moreInitial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with...
Read moreThe study, published in the journal Cell Reports Medicine, has shown in humans that acute exposure to cold increases the levels of oxylipins, compounds derived from omega-3 and omega-6 polyunsatura...
Read moreResearchers at IDIBAPS-Hospital Clínic Barcelona are leading a study that has found links between rising temperatures and an increase in suicide. Published in the journal World Psychiatry, the study ...
Read moreThe combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell ...
Read moreVIVEbiotech has been awarded the prize “New Company of Gipuzkoa 2024” by ADEGI, Business Association of Gipuzkoa.
Read moreOryzon Genomics, S.A., announced today that the final results of the Phase IIa ALICE study evaluating iadademstat in combination with azacitidine in unfit patients with newly diagnosed acute myeloid l...
Read more